LUNGevityHunter Posted December 3, 2021 Share Posted December 3, 2021 Visit https://merckoncologyclinicaltrials.com/en-us/patient/trial/NCT04624204 or call 888-577-8839 for more information KEYLYNK-013 - Placebo-controlled study of concurrent chemoradiation therapy with Pembrolizumab followed by Pembrolizumab and Olaparib in newly diagnosed, treatment-naïve limited-stage small cell lung cancer (LS-SCLC) (NCT04624204) You can be in this trial if you have newly diagnosed LS-SCLC and have not yet had treatment. The drug you get will depend on which group you are placed in. You have a 1 in 3 chance of being placed in each group. This trial has 3 groups: Group 1: Pembro with chemotherapy and radiation followed by pembro and olaparib placebo Group 2: Pembro with chemotherapy and radiation followed by pembro and olaparib Group 3: Pembro placebo with chemotherapy and radiation followed by pembro placebo and olaparib placebo You, your trial doctor, and the trial staff won’t know what drug you are getting. In case of a health emergency, they can find out. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.